The A.L.S. Family Charitable Foundation is dedicated to the care of patients and families affected by A.L.S. TODAY and the cure for A.L.S. in the FUTURE.
If you or someone you know has been diagnosed with A.L.S. and lives in the New England area, please contact us at 508.759.9696 or email This e-mail address is being protected from spambots. You need JavaScript enabled to view it . To read about the programs we offer for patients and their families, please view our Patient Programs.
In addition to patient services, we offer financial contributions to the following medical research institutions:
Dr. Robert Brown, Department Chair of Neurology at the UMass Memorial Medical Center and Umass Medical School
Dr. Brown has been conducting research for finding the cure for A.L.S. since 1979. Recently appointed the head of neurology at University of Massachusetts Medical School and UMass Memorial Medical Center, Dr. Brown is single-minded in his determination to find better treatments for the devastating diagnosis of A.L.S. and hopes to find a faster pathway to treatments at the state's medical school. Dr. Brown has produced some of the most cutting-edge and creative projects in A.L.S. research during his work in the past 30 years.
The David M. Dorfman Research Fund for Today's A.L.S. Patients: A.L.S. TDI
The mission of the A.L.S. Therapy Development Institute (A.L.S. TDI) is to develop effective therapeutics that stop ALS as soon as possible. Focused on meeting this urgent unmet medical need, A.L.S. TDI executes a robust discovery program, as well as a multi-pronged approach to validate potential therapeutics; including small molecules, protein biologics, gene therapies and cell-based constructs. The Institute's unique, industrial-scale platform allows for the development and testing of dozens of potential therapeutics each year. Built by and for patients, the Institute is the world's largest A.L.S. research center and the only nonprofit biotechnology company with more than 30 professional scientists focused on a single disease indication. In addition, the Cambridge, Massachusetts based research Institute collaborates with leaders in both academia and industry.
